Kimberly Rath, PharmD

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

A national analysis of CDC data over 25 years revealed persistent sex, racial, and regional disparities in pneumonia and pulmonary fibrosis mortality.

An IPF-derived biomarker profile shows a reproducible association with ILD risk across three RA cohorts.

A new population pharmacokinetic and exposure-response analyses shows no added efficacy or safety benefit from higher doses of serplulimab.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Structural and microbial findings point to a potential nasal-brain immune connection in patients with multiple sclerosis (MS).

A multidisciplinary approach that includes addressing social determinants of health reduces time to remission despite higher initial costs.

Serum biochemical fingerprints can stratify chronic lymphocytic leukemia (CLL) outcomes and uncover heterogeneity within molecularly defined low-risk disease.

Tumor-first multigene testing boosts diagnostic accuracy, minimizes duplication, and aligns with professional society recommendations for integrated sequencing.

Metallomic correlations suggest environmental and metabolic metals act together to accelerate renal damage.

Integrated data suggest higher tryptophan activity is associated with reduced inflammation and improved outcomes in RA.

Lesion-based disconnectome mapping suggests that the pattern, not the quantity, of brain damage determines cognitive outcomes in patients with MS.

A machine learning–driven web tool based on 13 standard patient metrics demonstrates strong predictive performance for MASLD, supporting early clinical intervention.

Patients with NOTCH1 mutations derive greater benefit from BTK inhibitor treatment than from immunochemotherapy for chronic lymphocytic leukemia (CLL).

DMARD nonadherence rates in patients with RA range from 0% to 100%, with inconsistent measurement tools and few validated interventions.

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

Treating constipation with lubiprostone may confer renal benefits in chronic kidney disease by modulating microbiome-driven pathways.

Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy.

A recent study outlines how artificial intelligence advancements are transforming research and therapeutic strategies for idiopathic pulmonary fibrosis.

Multidisciplinary care influenced therapy choices but did not substantially shorten treatment delays for patients with sarcoma.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Findings reveal that alternative polyadenylation regulates SASP factors and may fuel age-related pulmonary fibrosis.

The chronic spontaneous urticaria treatment landscape has shifted in recent years, with expanding treatment options for patients with refractory disease.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

A primary care–based collaborative care model significantly cut opioid use, though mental health outcomes remained unchanged.

Novel 3D analysis reveals core tumor niches drive resistance through AP-1 signaling and stromal reprogramming.

A qualitative study found strong support for primary care provider–nephrologist comanagement of chronic kidney disease (CKD), but persistent deficits in CKD understanding remain.

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.